Your Commercial Data Has a Quality Problem, Not a Pipeline Problem: A Framework for Life Sciences Teams
The pipeline works. Data flows from CRM to warehouse to dashboard on schedule, every morning. And yet the forecast is off, the territory model doesn’t match reality, and the AI vendor you onboarded six months ago still hasn’t delivered a usable output. The pipeline isn’t the problem. The data moving through it is.
This pattern shows up consistently in growth-stage pharma and biotech companies, and it almost always traces back to the same root cause: data quality gets treated as a cleanup task, something to handle after the fact when a report looks wrong or a VP asks an uncomfortable question. It never gets treated as infrastructure. That gap is quiet, and it compounds fast.
Why “We’ll Clean It Later” Always Fails
Here is what “clean it later” actually looks like in practice. Your sales ops team builds a territory model using HCP affiliation data that was last validated eight months ago. A physician moved practices, two accounts merged, and one high-value target retired. Nobody flagged those changes in the CRM because the process for flagging them doesn’t exist. The model ships with stale inputs baked in, the field team works the wrong accounts for a quarter, and by the time anyone investigates, the data problem has already cost real revenue.
Now add a compliance layer. You’re handling prescriber data, patient support program records, or third-party claims feeds. HIPAA requires that PHI be handled with defined access controls, audit trails, and data minimization. SOX may apply if you’re public or pre-IPO. State privacy laws add more. None of these frameworks care whether your data quality issues were accidental. If your pipelines can’t demonstrate provenance and access controls at the field level, you carry compliance risk on top of analytical risk. Those two failure modes together are what make this problem load-bearing.
A Practical Data Quality Framework for Life Sciences Commercial Data
The framework that works in this context has four layers, each building on the one below it. Think of it as a stack, not a checklist.
Layer 1: Define fitness for purpose, not perfection. The most common mistake in data quality programs is treating “quality” as a universal standard. It isn’t. A field that needs 99.9% accuracy for a payer contract analysis may only need 85% accuracy for a territory heatmap. Start by mapping your data assets to their downstream uses, then define explicit quality thresholds for each use case. This sounds obvious, but most teams skip it and end up running expensive validation on fields that don’t affect any decision, while ignoring completeness gaps in fields that do. Document these thresholds in a data contract, a formal agreement between the producer of a dataset and the consumers of it. A data contract makes quality a first-class concern at ingestion, not at reporting.
Layer 2: Instrument your pipelines with quality checks, not just monitors. There is a meaningful difference between monitoring and enforcement. Monitoring tells you something went wrong. Enforcement stops the bad data from propagating. Build quality checks directly into your ingestion and transformation logic using tools like dbt tests, Great Expectations, or Soda. Check for null rates, referential integrity, distribution drift, and format conformance at every layer of your pipeline. When a check fails, route the data to a quarantine state rather than letting it flow downstream. Flag it, log it, and alert the data owner. This is the architectural move that separates teams who catch data problems before they corrupt a forecast from teams who find out six weeks later.
Layer 3: Build a data lineage and provenance model. For life sciences commercial data, lineage is not optional. You need to be able to answer, for any dataset, three questions: Where did this data come from? Who has touched it? What transformations were applied? This matters for compliance because regulators can and do ask those questions. It also matters for debugging, because when your AI model produces a strange output, you need to trace it back to the upstream input that caused it. Tools like dbt’s lineage graph, OpenLineage, or purpose-built data catalog platforms (Atlan, Alation) make this tractable without requiring a dedicated data governance team. At minimum, document source-to-consumption lineage in your warehouse layer, and log all transformation logic in version-controlled SQL or Python.
Layer 4: Own the quality of your reference data. This is the layer most commercial teams underinvest in, and it’s where the worst problems hide. Reference data is the foundation everything else joins to: HCP and HCO master data, account hierarchies, territory alignments, product taxonomies. If your reference data is stale or inconsistent, every downstream analysis inherits those errors silently. Establish a cadence for validating and refreshing reference data from authoritative sources (Veeva, IQVIA, Symphony, or internal MDM systems). Define a single system of record for each reference entity and enforce it. If two systems disagree on a physician’s primary affiliation, that conflict needs a resolution process, not a shrug.
The Life Sciences Context That Changes Everything
Growth-stage pharma and biotech teams operate under constraints that make generic data quality advice nearly useless. You rarely have a dedicated data governance team. Your commercial data stack is often assembled from point solutions (a CRM here, a data provider feed there, a homegrown attribution model in the middle) rather than designed as a coherent system. And you’re subject to compliance obligations that most enterprise data frameworks don’t account for. HIPAA-compliant data pipelines require field-level access controls, audit logging, and data retention policies baked into the architecture, not bolted on afterward. If you’re handling prescriber data under state aggregate spend laws, or patient data through a hub program, those requirements extend into your warehouse and your BI layer. The framework above accounts for this by building compliance controls into layers two and three, making them structural rather than procedural.
The Readiness Question You Should Be Asking
If you’re planning to use AI for anything in your commercial function, whether that’s forecasting, next-best-action, segmentation, or market access analytics, your data quality framework is the thing that determines whether that investment pays off. AI models don’t fail loudly on bad data. They fail quietly, producing outputs that look plausible but reflect the errors in their inputs. The teams that get value from AI in commercial life sciences are the ones who treated data quality as infrastructure before they started the AI project.
If you’re not sure where your stack stands on any of these four layers, that’s exactly the kind of diagnostic Vida Solutions was built to run. We work with commercial data teams at pharma and biotech companies to design pipelines that are accurate, compliant, and ready for the analytical workloads you’re actually building toward. The conversation starts with what you have, not what you wish you had.
